Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Abstract Background. The ongoing search for more effective agents in the treatment of uterine leiomyosarcomas is warranted because of the poor prognosis related to these tumors. Case. A case of advanced, recurrent and refractory uterine leiomyosarcoma is presented that responded to trabectedin (ET-743) 1.2 mg/m2 intravenously over 24 h every 3 weeks after failing four prior regimens. A durable objective response lasting at least 8 months was documented. Conclusion. Trabectedin (ET-743) has activity in uterine leiomyosarcoma and warrants further investigation.